Sign in
CompletedPhase 4

Parecoxib in Total Knee Arthroplasty

Key facts

Who runs it
University of Chile
Where
Chile1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
40 people enrolled
Started
6 Jul 2023
Ended
1 Sept 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Intravenous study drug
  • Intravenous saline solution
Record updated
15 May 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • ASA I - III BMI 20 - 35 (kg/m2)

Who cannot take part

  • Allergy to local anesthetics, morphine, paracetamol, ketorolac or parecoxib
  • Chronic pain syndromes that require the use of opioids at home
  • Known history of sulfa allergy
  • History of ischemic heart disease
  • History of chronic gastritis or peptic ulcer
  • Coagulation disturbance (assessed on history and physical examination, if clinically necessary, by blood test, i.e. platelets ≤ 100,000, international normalized ratio ≥ 1.4 or prothrombin time ≥ 50)
  • Renal failure (assessed by history and physical examination, if considered clinically necessary, by blood test, i.e. creatinine ≥ 1.04 mg/dl)
  • Hepatic impairment (assessed by history and physical examination, if considered clinically necessary, by blood tests, i.e. transaminases (GGT ≥ 50 u/lt)
  • Adults who are not capable of giving their own consent
  • Pre-existing neuropathy (assessed in the history and physical examination)
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Early mobilization and rehabilitation can be difficult after total knee arthroplasty (TKA) due to a high incidence of moderate to severe postoperative pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are important to multimodal analgesic protocols. Parecoxib is an NSAID that selectively inhibits the enzyme cyclooxygenase-2 (COX-2). Clinical trials have shown that it does not alter platelet function or gastric mucosa. A recent study, after comparing ketorolac and parecoxib used at the same time in infiltration and systemically, found no differences in perioperative analgesia with a tendency to less bleeding in the parecoxib group. This randomized study will compare the effectiveness of adding a COX-2 inhibitor in the pain management of patients undergoing TKA as part of a multimodal analgesia regimen. The morphine consumption was selected as the primary outcome. The study hypothesis is that patients receiving parecoxib would have a lower opioid consumption.

The 2 groups in the trial

  • ParecoxibTreatment being tested

    This arm will receive intravenous parecoxib in the intraoperative period.

    Treatment: Intravenous study drug

  • PlaceboPlacebo, for comparison

    This arm will receive a placebo intravenous injection containing saline solution in the same volume as the intervention group

    Treatment: Intravenous saline solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Comparison Between Parecoxib and Placebo Added to a Standard Perioperative Analgesic Protocol for Total Knee Arthroplasty
Record updated
15 May 2025